Tag: ad

Doceree launches co-pay.com, an initiative to build the largest database of co-pay and affordability programs

SHORT HILLS, N.J. , July 22, 2025 /PRNewswire/ -- Doceree, the world's first global network for programmatic HCP engagement, has announced the launch of co-pay.com—the...

Lecanemab four-year efficacy and safety data to be presented at AAIC 2025

STOCKHOLM, July 22, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including...

K Wave Media 宣布获得 Galaxy Digital 投资并与之建立战略合作伙伴关系，以此加速比特币金库战略的实施

纽约和韩国首尔, July 22, 2025 (GLOBE NEWSWIRE) -- K Wave Media（纳斯达克股票代码：KWM），一家比特币金库与韩国文化创新公司，自豪地宣布其与全球领先的数字资产投资公司之一 Galaxy Digital（纳斯达克股票代码：GLXY）建立了战略合作伙伴关系。

K Wave Media 宣布與 Galaxy Digital 建立投資和戰略合作夥伴關係，加快發展比特幣財資策略

紐約及首爾，韓國, July 22, 2025 (GLOBE NEWSWIRE) -- 比特幣財資及韓國文化創新公司 K Wave Media（Nasdaq：KWM） 自豪地宣布與全球數一數二的數碼資產投資公司 Galaxy Digital（Nasdaq：GLXY）建立戰略合作夥伴關係。

Project Odyssey Season 3 Premieres August 29 – 3,000+ Creators, 100+ Countries & a Las Vegas Gala Finale

San Francisco, CA , July 21, 2025 (GLOBE NEWSWIRE) -- Project Odyssey, the world’s largest AI filmmaking competition opens submissions August 29, 2025 for Season 3. This season is projected to feature over 10,000 AI‑generated films from more than 3,000 creators across 100+ countries, before culminating in a hybrid red‑carpet gala and livestream in mid‑November.

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI^® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.

EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...

Pixalate’s June 2025 Delisted Mobile Apps Reports: 46,331 Apps Delisted from Google Play Store & 45,685 from Apple App Store

Pixalate research finds 12,790 apps delisted from the United States (U.S.) Google Play Store were ad-enabled (e.g., had an app-ads.txt file), while 3,789 apps delisted from the Apple App Store were ad-enabled

Pixalate research finds 12,790 apps delisted from the United States (U.S.) Google Play Store were ad-enabled (e.g., had an app-ads.txt file), while 3,789 apps delisted from the Apple App Store were ad-enabled

Nova Klúbburinn hf.: Framkvæmd endurkaupaáætlunar í viku 29

Í 29. viku 2025 keypti Nova Klúbburinn hf. 3.000.000 eigin hluti að kaupverði 14.628.000 kr. í samræmi við eftirfarandi:

Síminn hf. – Reglubundin tilkynning um kaup á eigin bréfum í samræmi við endurkaupaáætlun

Í 29. viku 2025 keypti Síminn hf. 2.000.000 eigin hluti að kaupverði 25.200.000 kr. skv. sundurliðun hér á eftir:

REITIR: Framkvæmd endurkaupaáætlunar í viku 29

Stjórn Reita fasteignafélags hf. samþykkti nýja endurkaupaáætlun félagsins þann 1. júlí 2025 sbr. tilkynningu í Kauphöll þann dag. Var henni hrint í framkvæmd þann 2. júlí 2025. Endurkaupaáætlunin er framkvæmd í samræmi við ákvæði hlutafélagalaga nr. 2/1995, 5. gr. reglugerðar Evrópuþingsins og ráðsins (ESB) um markaðssvik nr. 596/2014, sem og framselda reglugerð framkvæmdastjórnarinnar 2016/1052, samanber lög um aðgerðir gegn markaðssvikum nr. 60/2021.

Mission Media AI Partners with VSiN to Lead Advertising Sales Across Premium Sports Network

Mission Media AI to lead advertising sales for VSiN, The Sports Betting Network.

Kaldalón hf.: Reglubundin tilkynning um kaup á eigin bréfum í samræmi við endurkaupaáætlun

Í viku 29 árið 2025 keypti Kaldalón hf. 3.050.000 eigin hluti að kaupvirði kr. 76.460.000 skv. sundurliðun hér á eftir;

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease

Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsAd

ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WGS

Canada Council for the Arts invests $25 million to strengthen Alberta arts communities

Modat adds Passive DNS to its Platform Magnify, Connecting Every Signal in a Single Investigation Graph